Table 3.
Predictors of lost to follow-up in the first 36 months after ART initiation (Cox models)
| Variables | Number of lost to follow-up | Multivariable model
|
|
|---|---|---|---|
| HR (95% CI) | P-value | ||
|
| |||
| Age at ART initiation (years) | <0.0001 | ||
| 16–29 | 5,563 | 1 | |
| 30–39 | 8,515 | 0.83 (0.80–0.85) | |
| 40–49 | 4,929 | 0.76 (0.73–0.79) | |
| 50–59 | 1,802 | 0.78 (0.74–0.82) | |
| ≥60 | 546 | 0.97 (0.88–1.06) | |
| Gender | <0.0001 | ||
| Female | 13,465 | 1 | |
| Male | 7,890 | 1.23 (1.19–1.26) | |
| Year of ART initiation | <0.0001 | ||
| <2007 | 6,133 | 1 | |
| 2007–2010 | 7,100 | 1.01 (0.98–1.05) | |
| 2011 and after | 8,122 | 1.63 (1.57–1.69) | |
| Initial clinical stage | <0.0001 | ||
| A, B/I, II | 6,847 | 1 | |
| AIDS/III, IV | 5,377 | 1.12 (1.08–1.17) | |
| Missing | 9,131 | 1.23 (1.19–1.27) | |
| Initial CD4 cell count (cells/µL) | <0.0001 | ||
| ≥350 | 2,640 | 1 | |
| 200–349 | 3,947 | 0.91 (0.87–0.96) | |
| 100–199 | 3,810 | 0.96 (0.91–1.01) | |
| 50–99 | 2,302 | 1.14 (1.07–1.20) | |
| 0–49 | 3,436 | 1.30 (1.23–1.37) | |
| Missing | 5,220 | 1.00 (0.95–1.05) | |
| Initial hemoglobin (g/dL) | <0.0001 | ||
| ≥12 | 1,431 | 1 | |
| 10–12 | 2,691 | 1.20 (1.12–1.28) | |
| 7.5–10 | 2,528 | 1.42 (1.33–1.52) | |
| <7.5 | 707 | 1.64 (1.50–1.80) | |
| Missing | 13,998 | 1.46 (1.38–1.55) | |
| First ART regimen | <0.0001 | ||
| AZT+3TC/FTC+NVP/EFV | 5,617 | 1 | |
| D4T+3TC/FTC+NVP/EFV | 3,889 | 1.08 (1.04 –1.13) | |
| TDF+3TC/FTC+NVP/EFV | 2,833 | 1.11 (1.06–1.16) | |
| Others/unknown | 9,016 | 1.38 (1.33–1.44) | |
| BMI (kg/m2) | <0.0001 | ||
| 18–25 | 4,855 | 1 | |
| <18 | 1,950 | 1.19 (1.13–1.26) | |
| ≥25 | 1,255 | 0.93 (0.87–0.99) | |
| Missing | 13,295 | 2.07 (1.99–2.15) | |
| Total number of patients started ART in 2014–2015 and still in care, in the facility | <0.0001 | ||
| <500 | 8,081 | 1 | |
| 500–1,000 | 8,600 | 1.02 (0.98–1.05) | |
| ≥1,000 | 4,674 | 0.71 (0.68–0.74) | |
Abbreviations: ART, antiretroviral therapy; BMI, body mass index.